187 related articles for article (PubMed ID: 32202662)
1. TERT and TERT promoter in melanocytic neoplasms: Current concepts in pathogenesis, diagnosis, and prognosis.
Motaparthi K; Kim J; Andea AA; Missall TA; Novoa RA; Vidal CI; Fung MA; Emanuel PO
J Cutan Pathol; 2020 Aug; 47(8):710-719. PubMed ID: 32202662
[TBL] [Abstract][Full Text] [Related]
2. Telomerase Reverse Transcriptase Protein Expression Is More Frequent in Acral Lentiginous Melanoma Than in Other Types of Cutaneous Melanoma.
Cho WC; Wang WL; Milton DR; Ingram DR; Nagarajan P; Curry JL; Ivan D; Lazar AJ; Hwu WJ; Prieto VG; Torres-Cabala CA; Aung PP
Arch Pathol Lab Med; 2021 Jul; 145(7):842-850. PubMed ID: 33053175
[TBL] [Abstract][Full Text] [Related]
3. Utility of TERT Promoter Mutations for Cutaneous Primary Melanoma Diagnosis.
Thomas NE; Edmiston SN; Tsai YS; Parker JS; Googe PB; Busam KJ; Scott GA; Zedek DC; Parrish EA; Hao H; Slater NA; Pearlstein MV; Frank JS; Kuan PF; Ollila DW; Conway K
Am J Dermatopathol; 2019 Apr; 41(4):264-272. PubMed ID: 30211730
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and implications of TERT promoter mutation in uveal and conjunctival melanoma and in benign and premalignant conjunctival melanocytic lesions.
Koopmans AE; Ober K; Dubbink HJ; Paridaens D; Naus NC; Belunek S; Krist B; Post E; Zwarthoff EC; de Klein A; Verdijk RM;
Invest Ophthalmol Vis Sci; 2014 Aug; 55(9):6024-30. PubMed ID: 25159205
[TBL] [Abstract][Full Text] [Related]
5. TERT Promoter Mutations Are Predictive of Aggressive Clinical Behavior in Patients with Spitzoid Melanocytic Neoplasms.
Lee S; Barnhill RL; Dummer R; Dalton J; Wu J; Pappo A; Bahrami A
Sci Rep; 2015 Jun; 5():11200. PubMed ID: 26061100
[TBL] [Abstract][Full Text] [Related]
6. TERT promoter mutations in atypical melanocytic lesions: A series of seven cases with adverse melanoma-specific outcome.
Huber R; Lee J; Borretta L; Tessier-Cloutier B; Lum A; Yip S; Horst BA
Hum Pathol; 2024 Feb; 144():34-39. PubMed ID: 38224873
[TBL] [Abstract][Full Text] [Related]
7. The role of TERT promoter mutations in differentiating recurrent nevi from recurrent melanomas: A retrospective, case-control study.
Walton KE; Garfield EM; Zhang B; Quan VL; Shi K; Mohan LS; Haugh AM; VandenBoom T; Yazdan P; Isales MC; Panah E; Gerami P
J Am Acad Dermatol; 2019 Mar; 80(3):685-693. PubMed ID: 30287318
[TBL] [Abstract][Full Text] [Related]
8. TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.
Griewank KG; Murali R; Puig-Butille JA; Schilling B; Livingstone E; Potrony M; Carrera C; Schimming T; Möller I; Schwamborn M; Sucker A; Hillen U; Badenas C; Malvehy J; Zimmer L; Scherag A; Puig S; Schadendorf D
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25217772
[TBL] [Abstract][Full Text] [Related]
9. A Clinicopathological Study of 29 Spitzoid Melanocytic Lesions With ALK Fusions, Including Novel Fusion Variants, Accompanied by Fluorescence In Situ Hybridization Analysis for Chromosomal Copy Number Changes, and Both TERT Promoter and Next-Generation Sequencing Mutation Analysis.
Kastnerova L; Martinek P; Grossmann P; Steiner P; Vanecek T; Kyclova J; Ferak I; Zalud R; Slehobr O; Svajdler P; Sulc M; Bradamante M; Banik M; Hadravsky L; Sticova E; Hajkova V; Ptakova N; Michal M; Kazakov DV
Am J Dermatopathol; 2020 Aug; 42(8):578-592. PubMed ID: 32701692
[TBL] [Abstract][Full Text] [Related]
10. TERT promoter mutation is uncommon in acral lentiginous melanoma.
Liau JY; Tsai JH; Jeng YM; Chu CY; Kuo KT; Liang CW
J Cutan Pathol; 2014 Jun; 41(6):504-8. PubMed ID: 24588324
[TBL] [Abstract][Full Text] [Related]
11. TERT promoter mutations are not always associated with poor prognosis in atypical spitzoid tumors.
Requena C; Heidenreich B; Kumar R; Nagore E
Pigment Cell Melanoma Res; 2017 Mar; 30(2):265-268. PubMed ID: 27930864
[No Abstract] [Full Text] [Related]
12. PRAME Immunohistochemical Expression and TERT Promoter Mutational Analysis as Ancillary Diagnostic Tools for Differentiating Proliferative Nodules From Melanoma Arising in Congenital Nevi.
Boutko A; Hagstrom M; Lampley N; Roth A; Olivares S; Dhillon S; Fumero-Velázquez M; Benton S; Zhao J; Zhang B; Dittmann D; Asadbeigi S; Busam KJ; Gerami P
Am J Dermatopathol; 2023 Jul; 45(7):437-447. PubMed ID: 37338065
[TBL] [Abstract][Full Text] [Related]
13. Classifying Melanoma by TERT Promoter Mutational Status.
Shaughnessy M; Njauw CN; Artomov M; Tsao H
J Invest Dermatol; 2020 Feb; 140(2):390-394.e1. PubMed ID: 31425705
[TBL] [Abstract][Full Text] [Related]
14.
Bai X; Kong Y; Chi Z; Sheng X; Cui C; Wang X; Mao L; Tang B; Li S; Lian B; Yan X; Zhou L; Dai J; Guo J; Si L
Clin Cancer Res; 2017 Oct; 23(20):6120-6127. PubMed ID: 28720667
[No Abstract] [Full Text] [Related]
15. Telomerase Expression in a Series of Melanocytic Neoplasms.
de Unamuno Bustos B; Sahuquillo Torralba A; Moles Poveda P; Pérez Simó G; Simarro Farinos J; Llavador Ros M; Palanca Suela S; Botella Estrada R
Actas Dermosifiliogr (Engl Ed); 2019 Apr; 110(3):212-219. PubMed ID: 30591199
[TBL] [Abstract][Full Text] [Related]
16. TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinoma.
Griewank KG; Murali R; Schilling B; Schimming T; Möller I; Moll I; Schwamborn M; Sucker A; Zimmer L; Schadendorf D; Hillen U
PLoS One; 2013; 8(11):e80354. PubMed ID: 24260374
[TBL] [Abstract][Full Text] [Related]
17. Ciliation Index Is a Useful Diagnostic Tool in Challenging Spitzoid Melanocytic Neoplasms.
Lang UE; Torres R; Cheung C; Vladar EK; McCalmont TH; Kim J; Judson-Torres RL
J Invest Dermatol; 2020 Jul; 140(7):1401-1409.e2. PubMed ID: 31978411
[TBL] [Abstract][Full Text] [Related]
18. Beclin 1 and LC3 autophagic gene expression in cutaneous melanocytic lesions.
Miracco C; Cevenini G; Franchi A; Luzi P; Cosci E; Mourmouras V; Monciatti I; Mannucci S; Biagioli M; Toscano M; Moretti D; Lio R; Massi D
Hum Pathol; 2010 Apr; 41(4):503-12. PubMed ID: 20004946
[TBL] [Abstract][Full Text] [Related]
19. Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness.
Macerola E; Loggini B; Giannini R; Garavello G; Giordano M; Proietti A; Niccoli C; Basolo F; Fontanini G
Virchows Arch; 2015 Aug; 467(2):177-84. PubMed ID: 26055532
[TBL] [Abstract][Full Text] [Related]
20. TERT amplification but not activation of canonical Wnt/β-catenin pathway is involved in acral lentiginous melanoma progression to metastasis.
Ramani NS; Aung PP; Gu J; Sfamenos S; Sdringola-Maranga C; Nagarajan P; Tetzlaff MT; Curry JL; Ivan D; Diab A; Prieto VG; Hwu WJ; Torres-Cabala CA
Mod Pathol; 2020 Oct; 33(10):2067-2074. PubMed ID: 32404956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
